U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 6 of 6 results

Status:
US Approved Rx (2021)
First approved in 2017

Class:
PROTEIN



Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. Semaglutide is a once-daily glucagon-like peptide-1 analog that differs to others by the presence of an ac...
Status:
US Approved Rx (2016)
First approved in 2016

Class:
PROTEIN



Lixisenatide (trade name Adlyxin) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Status:
US Approved Rx (2014)
First approved in 2014

Class:
PROTEIN

Status:
US Approved Rx (2010)
First approved in 2010

Class:
PROTEIN


Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liragluti...
Status:
US Approved Rx (2005)
First approved in 2005

Class:
PROTEIN



Exenatide (exendin-4) is sold under the brand name BYETTA to improve glycemic control in people with type 2 diabetes mellitus. Exenatide is a glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion by the pa...
Status:
US Previously Marketed
First approved in 2014

Class:
PROTEIN